Edition:
India

Perrigo Company PLC (PRGO.N)

PRGO.N on New York Stock Exchange

75.04USD
1:32am IST
Change (% chg)

$-0.86 (-1.13%)
Prev Close
$75.90
Open
$76.05
Day's High
$76.13
Day's Low
$74.55
Volume
258,046
Avg. Vol
316,854
52-wk High
$95.82
52-wk Low
$63.69

Latest Key Developments (Source: Significant Developments)

Perrigo Expects Complete Response Letter On Generic Version Of Proair
Saturday, 12 May 2018 

May 11 (Reuters) - Perrigo Company PLC ::PERRIGO EXPECTS COMPLETE RESPONSE LETTER ON GENERIC VERSION OF PROAIR®.PERRIGO COMPANY PLC - COMPANY DOES NOT EXPECT TO MEET ITS GOAL OF LAUNCHING A GENERIC VERSION OF PROAIR IN Q4 OF 2018.PERRIGO COMPANY - DOES NOT EXPECT TO ACHIEVE ABOUT $0.09 PER SHARE BENEFIT THAT WAS INCLUDED IN 2018 REPORTED & ADJUSTED EPS GUIDANCE RANGE.PERRIGO - EXPECTS TO RECEIVE A COMPLETE RESPONSE LETTER FROM U.S. FDA REGARDING ITS ANDA FOR ITS GENERIC VERSION OF PROAIR INHALATION AEROSOL.  Full Article

Impax Launches Generic Version Of Estrace Cream
Friday, 6 Apr 2018 

April 6 (Reuters) - Impax Laboratories Inc ::IMPAX LAUNCHES A GENERIC VERSION OF ESTRACE® CREAM (ESTRADIOL VAGINAL CREAM, USP, 0.01%).IMPAX LABORATORIES INC - ‍LAUNCHED GENERIC VERSION OF ESTRACE CREAM​​.  Full Article

Perrigo CEO Buys 7,500 Shares Of Co's Ordinary Shares On March 5
Thursday, 8 Mar 2018 

March 7 (Reuters) - Perrigo Company Plc ::PERRIGO CEO UWE ROEHRHOFF REPORTS PURCHASE OF 7,500 SHARES OF CO'S ORDINARY SHARES ON MARCH 5 - SEC FILING.  Full Article

Perrigo Announces Final FDA Approval And Planned Launch For The Store Brand OTC Equivalent Of Mucinex DM Maximum Strength Extended Release Tablets
Wednesday, 7 Mar 2018 

March 7 (Reuters) - Perrigo Company Plc ::PERRIGO ANNOUNCES FINAL FDA APPROVAL AND PLANNED LAUNCH FOR THE STORE BRAND OTC EQUIVALENT OF MUCINEX® DM MAXIMUM STRENGTH EXTENDED RELEASE TABLETS.PERRIGO - ‍FINALIZING PLANS TO LAUNCH CO'S STORE BRAND EQUIVALENT OF MUCINEX DM MAXIMUM STRENGTH FOR 2018 COUGH-COLD SEASON​.  Full Article

Perrigo Company Reports Select Preliminary Unaudited 2017 Financial Results
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Perrigo Company Plc ::REPORTS SELECT PRELIMINARY UNAUDITED CALENDAR YEAR 2017 FINANCIAL RESULTS.PERRIGO COMPANY - ‍WILL RESCHEDULE ITS Q4 AND FISCAL YEAR 2017 FINAL EARNINGS RELEASE AND CONFERENCE CALL, PREVIOUSLY SCHEDULED FOR FEBRUARY 27, 2018​.PERRIGO COMPANY - ‍CO NEEDS ADDITIONAL TIME TO COMPLETE ITS FINAL INCOME TAX REVIEW PROCEDURES RELATED TO RECONCILIATIONS OF SPECIFIC NON-CASH ITEMS​.‍COMPANY IS WORKING TO COMPLETE ITS YEAR-END TAX REVIEW PROCEDURES​.  Full Article

Perrigo Appoints Ronald Winowiecki As CFO
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Perrigo Company Plc ::PERRIGO APPOINTS RONALD L. WINOWIECKI AS CHIEF FINANCIAL OFFICER.PERRIGO COMPANY PLC - RONALD L. WINOWIECKI HAS BEEN APPOINTED CHIEF FINANCIAL OFFICER.  Full Article

Perrigo Says In Connection With Uwe Röhrhoff's Appointment As CEO, Co's Unit Perrigo DAC Entered Into Employment Agreement With Him
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Perrigo Company Plc ::PERRIGO COMPANY - IN CONNECTION WITH UWE RÖHRHOFF'S APPOINTMENT AS CEO, CO'S UNIT PERRIGO DAC ENTERED INTO AN EMPLOYMENT AGREEMENT WITH HIM.PERRIGO COMPANY PLC - PERRIGO DAC EMPLOYMENT AGREEMENT HAS AN INITIAL TERM OF THREE YEARS.PERRIGO COMPANY PLC - PERRIGO DAC EMPLOYMENT AGREEMENT PROVIDES THAT RÖHRHOFF WILL BE ENTITLED TO AN ANNUAL BASE SALARY OF EUR 850,000.PERRIGO COMPANY PLC - RÖHRHOFF WILL ALSO RECEIVE A EUR 850,000 SIGN-ON BONUS, TO BE PAID EUR 425,000 IN CASH AND EUR 425,000 IN RSUS.PERRIGO SAYS RÖHRHOFF TO BE ENTITLED TO TARGET ANNUAL BONUS OPPORTUNITY OF NO LESS THAN 125% OF ANNUAL BASE SALARY- SEC FILING.  Full Article

Perrigo appoints Uwe Röhrhoff as CEO
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Perrigo Company Plc ::PERRIGO APPOINTS UWE RÖHRHOFF AS PRESIDENT & CHIEF EXECUTIVE OFFICER.PERRIGO COMPANY- ‍ANNOUNCED APPOINTMENT OF UWE RÖHRHOFF AS CHIEF EXECUTIVE OFFICER, EFFECTIVE JANUARY 15, 2018, FOLLOWING RETIREMENT OF JOHN T. HENDRICKSON​.‍JOHN T. HENDRICKSON TO REMAIN WITH COMPANY UNTIL MARCH 15, 2018 TO ENSURE SUCCESSFUL TRANSITION​.  Full Article

Perrigo Company ‍Launch AB Rated Generic Version Of Exalgo 32mg
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Perrigo Company Plc ::PERRIGO COMPANY PLC - ‍LAUNCH OF AN AB RATED GENERIC VERSION OF EXALGO 32MG EXTENDED RELEASE TABLETS C-II​.  Full Article

Perrigo Company completes divestiture of API business for $110 million
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Perrigo Company PLC :Perrigo Company completes divestiture of API business for $110 million.  Full Article

Photo

AbbVie, AndroGel partner owe $448 million in antitrust case: U.S. judge

A U.S. judge on Friday found that pharmaceutical company AbbVie Inc used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million.